Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | XBP1 | P17861 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | WNT3A | P56704 | 10/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5934290 | 0.86 | MAPT (0.56) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL5934313 | 0.85 | MAPT (0.57) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL5934792 | 0.82 | TRPV1 (0.62) | NPC1RAB9AWNT3ATRPV1KCNQ3 | |
| SCHEMBL5934513 | 0.82 | NPC1 (0.58) | MEN1KMT2ANPSR1HTTNPC1 | |
| SCHEMBL5934086 | 0.82 | MEN1 (0.58) | MAPTMEN1KMT2ALMNAWNT3A | |
| SCHEMBL5934547 | 0.80 | PTPN1 (0.61) | MEN1KMT2ALMNANPC1RAB9A | |
| SCHEMBL1543152 | 0.79 | KDM4E (0.60) | MEN1KMT2ANPC1RAB9AWNT3A | |
| SCHEMBL5934456 | 0.79 | WNT3A (0.54) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5934543 | 0.79 | NPC1 (0.54) | MAPTMEN1KMT2ALMNANPC1 | |
| SCHEMBL5934448 | 0.79 | RAB9A (0.55) | MAPTMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | HCAR2, AHR, HCAR3 | MAPT 3567/4885MEN1 4851/4885KMT2A 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.